AGN-241622 / AbbVie - LARVOL DELTA

Phase 1/2 Study of AGN-241622 in Healthy Participants and Participants With Presbyopia (clinicaltrials.gov) - P1/2 | N=80 | Terminated | Sponsor: AbbVie | N=144 ➔ 80 | Trial completion date: Jun 2023 ➔ Dec 2022 | Recruiting ➔ Terminated | Trial primary completion date: Jun 2023 ➔ Dec 2022; Company Decision

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Ophthalmology

Phase 1/2 Study of AGN-241622 in Healthy Participants and Participants With Presbyopia (clinicaltrials.gov) - P1/2 | N=144 | Recruiting | Sponsor: AbbVie | Trial primary completion date: Aug 2022 ➔ Jun 2023

Trial primary completion date • Ophthalmology

""As per #WHO, globally unaddressed #presbyopia POP. is 826 million" Current emerging therapies for Presbyopia: - BRIMOCHOL (@VisusTx) - Pilocarpine micro-formulation/MicroLine (@eyenovia /Arctic Vision) - AGN-241622 (@AbbVieUS) - Phentolamine mesylate (@ocuphire) @mellaltameets" (@mellaltameets)

Clinical • Ophthalmology

Phase 1/2 Study of AGN-241622 in Healthy Participants and Participants With Presbyopia (clinicaltrials.gov) - P1/2; N=144; Recruiting; Sponsor: Allergan; Trial completion date: Aug 2022 ➔ Jun 2023

Clinical • Trial completion date • Ophthalmology

Phase 1/2 Study of AGN-241622 in Healthy Participants and Participants With Presbyopia (clinicaltrials.gov) - P1/2; N=144; Recruiting; Sponsor: Allergan; Not yet recruiting ➔ Recruiting

Enrollment open • Ophthalmology

Phase 1/2 Study of AGN-241622 in Healthy Participants and Participants With Presbyopia (clinicaltrials.gov) - P1/2; N=144; Not yet recruiting; Sponsor: Allergan

Clinical • New P1/2 trial • Ophthalmology